Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in its Long-Acting Next Generation Psychedelic Compounds
Can you get the benefits of psilocybin without the trip? That’s what Mindset Pharma Inc. (MSET) is trying to determine.
The company recently developed a family of psilocybin analogs designed for microdosing. In preclinical studies, the compounds were found to have about 1/10th of the effect on 5-HT2A receptors as psilocybin, but with extended duration, which indicates that they will be ideal for once a day or once every other day dosing.
Mindset plans to test the compounds in preclinical animal models to determine if microdosing has cognitive enhancing effects.